Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-16T22:35:10.317Z Has data issue: false hasContentIssue false

Exploring the evolution of Acinetobacter baumannii and Pseudomonas aeruginosa resistance during the COVID-19 era

Published online by Cambridge University Press:  26 March 2025

Emine Sehmen
Affiliation:
Department of Clinical Microbiolgy and İnfectious Disease, Gazi State Hospital, Samsun, Turkiye
Esmeray Mutlu Yılmaz
Affiliation:
Department of Clinical Microbiolgy and İnfectious Disease, Samsun Training and Research Hospital, Samsun, Turkiye
Sevim Yetkin Pusa
Affiliation:
Department of Clinical Microbiolgy and İnfectious Disease, Gazi State Hospital, Samsun, Turkiye
Metin Özdemir
Affiliation:
Department of Clinical Microbiolgy and İnfectious Disease, Gazi State Hospital, Samsun, Turkiye
Yavuz Yiğit*
Affiliation:
Department of Emergency Medicine, Hamad Medical Corporation, Doha, Qatar
*
Corresponding author: Yavuz Yiğit; Email: yyigit@hamad.qa

Abstract

Aim:

In our study, we aim to compare the resistance profiles of Acinetobacter baumannii and Pseudomonas aeruginosa isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.

Materials:

The study involved adult patients monitored in the ICUs of a secondary-level hospital from January 2019 to December 2022. Isolates of A. baumannii and P. aeruginosa were obtained from blood, urine, and respiratory samples. Identification and antibiotic susceptibility tests were conducted using the disk diffusion method and the VITEK 2 system.

Results:

The average age of the patients was 61.3 ± 21.9 years (range: 18–95), with a majority of 1306 (51.6%) being male. During the pandemic, A. baumannii isolates showed a significant increase in resistance rates for several antibiotics compared to the pre-pandemic period: imipenem (96% vs 35.1%), amikacin (84.1% vs 14.4%), ciprofloxacin (96.9% vs 36.9%), trimethoprim-sulfamethoxazole (66.4% vs 27%), and ceftazidime (96.5% vs 33.3%) (all with P < .001). However, there was no significant change in colistin resistance rates in these isolates (0.9% vs 0%; P = .307). Similarly, Pseudomonas aeruginosa isolates exhibited significant increases in resistance rates during the pandemic compared to the pre-pandemic period: imipenem (51.5% vs 18.8%; P < .001), colistin (4.9% vs 0.6%; P = .009), amikacin (23.5% vs 4.4%; P < .001), ciprofloxacin (53.3% vs 13.8%; P < .001), and ceftazidime (39.2% vs 12.7%; P < .001).

Conclusion:

Our results demonstrate a significant increase in antibiotic resistance levels in Acinetobacter and Pseudomonas strains associated with hospital-acquired infections or colonization during the COVID-19 pandemic.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Distribution of the cultures

Figure 1

Figure 1.Change in resistance rates througout the years in Acinetobacter baumanni isolates.

Figure 2

Table 2.Resistance rates in non-fermantary bacteria

Figure 3

Figure 2.Change in resistance rates througout the years in Pseudomonas aeruginosa isolates.